Podcasts
Listen to the latest hemonc news from international experts
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
Exploring and comparing the curative potential of CAR-T therapy & bispecific antibodies in R/R DLBCL
The treatment and management of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) remains a major unmet need, and in recent years, the introduction of immunotherapies including CAR-T cells and bispecific antibodies has provided hope for several patients.
While both CAR-T cells and bispecific antibodies have their benefits, there are several factors to consider when evaluating their curative potential in R/R DLBCL. In this podcast, you will hear from Manali Kamdar, MD, University of Colorado, Aurora, CO, Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, and Gloria Iacoboni, MD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, who share some insights into the value of CAR-T cells and bispecifics in R/R DLBCL, the benefits and drawbacks of these agents, and further comment on their efficacy and curative potential.
Date: 23rd August 2023
